Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment : vimarsana.com

Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment


Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte (INCY) announced positive topline results from the late-stage study of baricitinib for the treatment of adults with severe alopecia areata (AA), an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress.
The phase III study of once-daily baricitinib 2-mg and 4-mg, dubbed BRAVE-AA2, met the primary efficacy endpoint at Week 36, showing a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo, the companies said.

Related Keywords

Japan , Eli Lilly , European Union , Lilly , Incyte , Report , Positive , Results , Baricitinib , Alopecia , Areata , Treatment , ஜப்பான் , எலி லில்லி , ஐரோப்பிய தொழிற்சங்கம் , லில்லி , அறிக்கை , பாஸிடிவ் , முடிவுகள் , அலோபீசியா , அரேட்டா , சிகிச்சை ,

© 2024 Vimarsana